All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How might treatment with venetoclax plus HMAs improve quality of life and post-transplant outcomes?
Bookmark this article
During the European Hematology Association (EHA) 2023 Hybrid Congress, the AML Hub was pleased to speak with Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, “How might treatment with venetoclax plus hypomethylating agents (HMAs) improve quality of life and post-transplant outcomes?”
How might treatment with venetoclax plus HMAs improve quality of life and post-transplant outcomes?
DiNardo begins by describing patient-reported outcomes and quality-of-life data from the VIALE-A study presented at EHA 2023, including EORTC QLQ-C3, PROMIS-fatigue, and EQ-5D-5L measures. She also discusses the clinical response and survival rates of patients who received venetoclax and HMA treatment prior to transplant, including the relevance of patient age and performance status.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox